Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Curr Probl Cancer ; 45(1): 100622, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-32800689

RESUMO

BACKGROUND: Methotrexate is the most common first-line chemotherapy for low-risk gestational trophoblastic neoplasia (GTN). Uterine artery pulsatility index (UAPI) is an ultrasound marker for tumor vascularity that has been associated with an increased risk of methotrexate resistance. The combination of circulating angiogenic factor levels with UAPI data may improve the capacity of this model to predict chemoresistance. METHODS: This was a single-center cohort study of women newly diagnosed between January 2008 and June 2012 with low-risk GTN during postmolar surveillance and treated with single-agent methotrexate at Charing Cross Hospital, a UK national center for treatment of gestational trophoblastic disease. Two hundred seventeen women underwent an ultrasound for UAPI measurement prior to initiation of chemotherapy. To examine serologic markers of methotrexate resistance among this cohort, we performed a case-control study using archived serum from 76 patients who could be matched based on prognostic risk score. Serum samples were examined by immunoassay to measure 8 different angiogenic factors (VEGF-A, FGF-basic, PLGF-1, PDGF-BB, EGF, ANGPT2, BMP-9, and ENG). Receiver-operator characteristic area under the curve (AUC) values were calculated for the ability of each analyte to correctly classify patients as methotrexate sensitive (MTX-S) or resistant (MTX-R). RESULTS: Total human chorionic gonadotropin levels were similar between the MTX-S and MTX-R groups. UAPI values were significantly higher in MTX-S (median 1.30 [interquartile range {IQR} = 0.80-1.90]) compared to MTX-R patients (median 0.875 [IQR = 0.60-1.30]; P < 0.0001) with AUC 0.68 (95% confidence interval 0.61-0.76; P < 0.0001). In univariate analysis, only BMP-9 concentrations were significantly different between groups, lower among MTX-S (median of 225 ng/L, IQR = 170-287) compared to MTX-R patients (median 280 ng/L [IQR = 200-339]; P= 0.03). Combining UAPI with BMP-9 concentration improved prediction for chemoresistance with AUC 0.77 (95% confidence interval 0.66-0.88; P < 0.0001). CONCLUSION: Circulating levels of BMP-9 are elevated in newly diagnosed women with low-risk GTN destined to fail primary methotrexate therapy. A combined test using serum BMP-9 plus UAPI might improve prediction of MTX-R in low-risk GTN.


Assuntos
Antimetabólitos Antineoplásicos/farmacologia , Resistencia a Medicamentos Antineoplásicos , Doença Trofoblástica Gestacional/tratamento farmacológico , Fator 2 de Diferenciação de Crescimento/sangue , Metotrexato/farmacologia , Artéria Uterina/fisiopatologia , Biomarcadores Tumorais/sangue , Estudos de Coortes , Feminino , Fator 2 de Diferenciação de Crescimento/efeitos dos fármacos , Humanos , Gravidez , Reino Unido , Artéria Uterina/diagnóstico por imagem
2.
J Vasc Access ; 19(2): 162-166, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29218696

RESUMO

INTRODUCTION: Access surgery is delivered by vascular/transplant surgeons with a division that is defined by historic practice. This has resulted in an inconsistent training pattern. We aimed to design a focused, modular training program (The Brighton Vascular Access Fellowship) providing trainees with a reproducible level of exposure and competence. METHODS: The programme was 16 days over 8 weeks on a one-to-one basis with candidates expected to be performing procedures as first surgeon with ongoing, formative assessment. The outpatient setting took the format of a one-stop clinic to involve planning and the follow-up. Assessment was through caseload exposure and conventional statistical analyses to obtain median values (as proxy measures of training exposure consistency). Assessment of confidence and capability was through an electronically distributed qualitative survey tool. RESULTS: A total of 14 candidates completed the programme by June 2017. Operative exposure was obtained for 11 (79%) with a total of 471 cases of which 286 were conducted as first surgeon. There was a median of 32 cases by each candidate with 25 of the cases performed as first surgeon. Qualitative assessment revealed that 13 of 14 (93%) were either practicing independently or no longer required the trainer to scrub in for the operation. A total of 13 of 14 (93%) strongly agreed that they felt comfortable with offering a basic access service. CONCLUSIONS: Focused modular training might be one of the answers to the current era of restricted and sometimes inconsistent training in some aspects of surgery. This model is reproducible and may be applicable in other aspects of training.


Assuntos
Derivação Arteriovenosa Cirúrgica/educação , Implante de Prótese Vascular/educação , Educação de Pós-Graduação em Medicina/métodos , Bolsas de Estudo , Cirurgiões/educação , Derivação Arteriovenosa Cirúrgica/efeitos adversos , Implante de Prótese Vascular/efeitos adversos , Competência Clínica , Currículo , Estudos de Viabilidade , Humanos , Curva de Aprendizado , Avaliação de Programas e Projetos de Saúde , Análise e Desempenho de Tarefas , Carga de Trabalho
3.
Am J Reprod Immunol ; 77(6)2017 06.
Artigo em Inglês | MEDLINE | ID: mdl-28295835

RESUMO

PROBLEM: Resistance to methotrexate is a leading clinical problem in gestational trophoblastic neoplasia (GTN), but there are limited laboratory models for this condition. METHOD OF STUDY: We created isogenic trophoblastic cell lines resistant to methotrexate and compared these to the parent cell lines using gene expression microarrays and qRT-PCR followed by mechanistic studies using recombinant cytokines, pathway inhibitors, and patient sera. RESULTS: Gene expression microarrays and focused analysis by qRT-PCR revealed methotrexate led to type I interferon upregulation, in particular interferon alpha 2 (IFNA2), and methotrexate resistance was associated with chronic low level increases in type I interferon expression. Recombinant IFNA2 imparted chemosensitive choriocarcinoma cells with partial resistance to methotrexate, while chemoresistant choriocarcinoma cells were uniquely sensitive to fludarabine, a STAT1 inhibitor. In pre-treatment patient sera, IFNA2 levels correlated with subsequent resistance to methotrexate chemotherapy. CONCLUSION: Methotrexate resistance is influenced by type I interferon signaling with prognostic and therapeutic implications for treating women with GTN.


Assuntos
Antimetabólitos Antineoplásicos/farmacologia , Resistencia a Medicamentos Antineoplásicos/imunologia , Doença Trofoblástica Gestacional/imunologia , Interferon Tipo I/imunologia , Metotrexato/farmacologia , Adulto , Linhagem Celular , Linhagem Celular Tumoral , Feminino , Doença Trofoblástica Gestacional/tratamento farmacológico , Doença Trofoblástica Gestacional/genética , Humanos , Gravidez , Transcriptoma
4.
EBioMedicine ; 4: 146-52, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26981554

RESUMO

Gestational trophoblastic neoplasia (GTN) represents a group of diseases characterized by production of human chorionic gonadotropin (hCG). Since non-gestational tumors may occasionally secrete hCG, histopathological diagnosis is important for appropriate clinical management. However, a histopathological diagnosis is not always available. We therefore investigated the feasibility of extracting cell free DNA (cfDNA) from the plasma of women with GTN for use as a "liquid biopsy" in patients without histopathological diagnosis. cfDNA was prepared from the plasma of 20 women with a diagnosis of GTN and five with hCG-secreting tumors of unknown origin. Genotyping of cfDNA from the patient, genomic DNA from her and her partner and DNA from the tumor tissue identified circulating tumor DNA (ctDNA) (from 9% to 53% of total cfDNA) in 12 of 20 patients with GTN. In one case without a tissue diagnosis, ctDNA enabled a diagnosis of GTN originating in a non-molar conception and in another a diagnosis of non-gestational tumor, based on the high degree of allelic instability and loss of heterozygosity in the ctDNA. In summary ctDNA can be detected in the plasma of women with GTN and can facilitate the diagnosis of both gestational and non-gestational trophoblastic tumors in cases without histopathological diagnosis.


Assuntos
Biomarcadores Tumorais/sangue , DNA/sangue , Doença Trofoblástica Gestacional/sangue , Adulto , Feminino , Humanos , Pessoa de Meia-Idade , Gravidez
6.
J Reprod Med ; 55(7-8): 285-95, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20795340

RESUMO

OBJECTIVE: To determine the ability of several radioimmunoassays and commercial two-site immunoassays to detect the first World Health Organization International Reference Reagents (IRRs) for 6 defined human chorionic gonadotropin (hCG) variants and to compare their performance in measuring hCG in sera from patients with gestational trophoblastic disease (GTD) and germ cell tumors (GCTs) of the testis or ovary. STUDY DESIGN: The reactivity of the different assays with the 6 IRRs together with the current fourth International Standard (IS, 75/589) was tested using 5 commercial two-site assays as well as 2 competitive polyclonal radioimmunoassays (RIAs) and a competitive monoclonal immunoassay. Individual samples from 41 patients (19 GCT and 22 GTD) with high circulating levels of hCG (range, 718-6,055,000 IU/L) were diluted and measured using the various immunoassays. RESULTS: The results of 4 GCT patient samples varied markedly among the assays, including 1 sample that was grossly underestimated by 3 of the commercial assays. CONCLUSION: Comparison of each assay's reactivity to the variant isoforms revealed that recognition of the isoforms was highly variable, particularly for hCGbeta and hCGbeta core fragment (hCGbetacf).


Assuntos
Coriocarcinoma/sangue , Gonadotropina Coriônica/sangue , Mola Hidatiforme Invasiva/sangue , Imunoensaio/métodos , Neoplasias Embrionárias de Células Germinativas/sangue , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Ovarianas/sangue , Gravidez , Neoplasias Testiculares/sangue , Neoplasias Uterinas/sangue
7.
J Reprod Med ; 53(8): 643-8, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18773632

RESUMO

OBJECTIVE: To evaluate the utility of free human chorionic gonadotropin beta-subunit (hCGbeta) proportion of total hCG measurement to distinguish placental site trophoblastic tumor (PSTT) from more common forms of gestational trophoblastic disease (GTD). STUDY DESIGN: Serum samples collected from PSTT, persistent trophoblastic disease (PTD) and choriocarcinoma patients were used for retrospective analysis of free hCGbeta-subunit. Results were reported as a percentage of total hCG using our in-house competitive radioimmunoassay. RESULTS: The percentage of free hCGbeta was significantly greater in serum from 18 PSTT patients, yielding a median value of 45.5% than in a combined GTD group of 49 PTD and 12 choriocarcinoma patients. Receiver operating characteristic analysis confirms that the percentage free hCGbeta distinguishes PSTT from GTD patients. Choriocarcinoma patients had significantly higher hCGbeta measurements than PTD patients and were not well distinguished from PSTT patients. CONCLUSION: Our findings show that an elevated proportion of free hCGbeta-subunit is a helpful but not definitive test to discriminate PSTT from other forms of GTD.


Assuntos
Biomarcadores Tumorais/sangue , Gonadotropina Coriônica Humana Subunidade beta/sangue , Tumor Trofoblástico de Localização Placentária/diagnóstico , Neoplasias Uterinas/diagnóstico , Adulto , Estudos de Coortes , Feminino , Humanos , Gravidez , Curva ROC
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...